G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Price:
1 407.6
INR
3.41%
Market Closed
Market Cap:
397.2B
INR
Cash Flow Statement
Cash Flow Statement
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Currency: INR
Millions
TTM
| Mar-2020 | Sep-2020 | Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
10 961
|
12 860
|
13 825
|
15 140
|
14 412
|
15 009
|
8 685
|
3 482
|
5 692
|
11 361
|
|
| Depreciation & Amortization |
4 172
|
4 496
|
4 436
|
4 626
|
4 867
|
5 529
|
6 113
|
6 180
|
6 308
|
5 596
|
|
| Other Non-Cash Items |
2 191
|
1 918
|
2 013
|
2 585
|
3 004
|
(1 591)
|
8 607
|
17 761
|
3 790
|
(2 298)
|
|
| Cash Taxes Paid |
4 670
|
4 526
|
5 102
|
5 674
|
5 584
|
5 517
|
6 405
|
5 585
|
10 475
|
12 480
|
|
| Cash Interest Paid |
3 015
|
2 725
|
2 936
|
2 674
|
2 505
|
2 782
|
3 115
|
4 100
|
5 168
|
3 740
|
|
| Change in Working Capital |
(3 399)
|
(6 977)
|
(8 961)
|
(9 860)
|
(11 197)
|
(11 259)
|
(17 144)
|
(20 225)
|
(20 362)
|
(30 019)
|
|
| Cash from Operating Activities |
13 924
N/A
|
12 296
-12%
|
11 312
-8%
|
12 490
+10%
|
11 087
-11%
|
7 689
-31%
|
6 261
-19%
|
7 198
+15%
|
(4 572)
N/A
|
(15 359)
-236%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
(9 324)
|
(8 361)
|
(7 748)
|
(7 079)
|
(7 901)
|
(7 710)
|
(6 078)
|
(6 890)
|
(9 149)
|
(7 502)
|
|
| Other Items |
1 489
|
984
|
995
|
4 736
|
4 568
|
626
|
793
|
676
|
54 758
|
62 263
|
|
| Cash from Investing Activities |
(7 835)
N/A
|
(7 377)
+6%
|
(6 752)
+8%
|
(2 342)
+65%
|
(3 333)
-42%
|
(7 084)
-113%
|
(5 285)
+25%
|
(6 214)
-18%
|
45 609
N/A
|
54 761
+20%
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
10 265
|
10 119
|
(146)
|
0
|
0
|
12
|
0
|
|
| Net Issuance of Debt |
(747)
|
(2 868)
|
(777)
|
(10 276)
|
(11 317)
|
1 963
|
5 234
|
7 799
|
(32 728)
|
(32 087)
|
|
| Cash Paid for Dividends |
(686)
|
(685)
|
(704)
|
(1 410)
|
(927)
|
(441)
|
(1 366)
|
(1 146)
|
(1 178)
|
(1 177)
|
|
| Other |
(3 015)
|
(2 725)
|
(2 936)
|
(3 247)
|
(3 079)
|
(4 310)
|
(4 643)
|
(4 100)
|
(5 168)
|
(3 740)
|
|
| Cash from Financing Activities |
(4 447)
N/A
|
(6 277)
-41%
|
(4 418)
+30%
|
(4 669)
-6%
|
(5 205)
-11%
|
(2 934)
+44%
|
(775)
+74%
|
2 553
N/A
|
(39 061)
N/A
|
(36 992)
+5%
|
|
| Change in Cash | |||||||||||
| Effect of Foreign Exchange Rates |
98
|
1 066
|
136
|
(64)
|
176
|
434
|
124
|
(269)
|
177
|
119
|
|
| Net Change in Cash |
1 740
N/A
|
(292)
N/A
|
278
N/A
|
5 415
+1 848%
|
2 725
-50%
|
(1 895)
N/A
|
325
N/A
|
3 268
+906%
|
2 152
-34%
|
2 530
+18%
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
4 600
N/A
|
3 935
-14%
|
3 564
-9%
|
5 411
+52%
|
3 186
-41%
|
(21)
N/A
|
183
N/A
|
308
+68%
|
(13 721)
N/A
|
(22 861)
-67%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
